UNITED STATES OF AMERICA —Biopharmaceutical software developer Simulations Plus has officially transitioned to a private enterprise following the completion of its transaction with healthcare-focused investment firm Altaris. Under the finalized terms, equity holders received $18.50 per share in cash, prompting the removal of the company's common stock from public trading venues.
Simulations Plus specializes in model-informed drug development, providing software and consulting solutions that utilize predictive analytics and quantitative systems pharmacology to optimize pharmaceutical research. The company's technology aids drug developers in predicting the safety, efficacy, and pharmacokinetic profiles of prospective therapeutic candidates across various stages of clinical trial design.
The buyout integrates Simulations Plus directly into the platform of Chemical Computing Group, an existing Altaris portfolio company known for its molecular modeling applications. By unifying these two technical architectures, the combined enterprise creates a comprehensive software ecosystem spanning early-stage target discovery through advanced clinical trial simulation. Although integrated operationally, Simulations Plus will preserve its corporate brand identity.
This transaction highlights an escalating demand across the global pharmaceutical sector for computational and artificial intelligence tools capable of mitigating clinical trial risks, reducing developmental timelines, and lowering capital expenditures. Biopharmaceutical entities, research institutions, and healthcare investors face an increasingly streamlined landscape for scientific software tools as private equity platforms continue to consolidate specialized modeling applications into end-to-end service suites.
For market participants, the privatization reflects ongoing private equity interest in high-margin, specialized software providers serving life sciences. The operational merger between biosimulation and molecular design technologies is poised to establish higher competitive benchmarks for computational drug platforms, encouraging further strategic dealmaking across the broader biotechnology and software sectors.
